Reading School of Pharmacy, University of Reading, Reading, UK.
Br J Pharmacol. 2013 Feb;168(3):576-90. doi: 10.1111/j.1476-5381.2012.02234.x.
The enzymatic activity of peptidases must be tightly regulated to prevent uncontrolled hydrolysis of peptide bonds, which could have devastating effects on biological systems. Peptidases are often generated as inactive propeptidases, secreted with endogenous inhibitors, or they are compartmentalized. Propeptidases become active after proteolytic removal of N-terminal activation peptides by other peptidases. Some peptidases only become active towards substrates only at certain pHs, thus confining activity to specific compartments or conditions. This review discusses the different roles proteolysis plays in regulating GPCRs. At the cell-surface, certain GPCRs are regulated by the hydrolytic inactivation of bioactive peptides by membrane-anchored peptidases, which prevent signalling. Conversely, cell-surface peptidases can also generate bioactive peptides, which directly activate GPCRs. Alternatively, cell-surface peptidases activated by GPCRs, can generate bioactive peptides to cause transactivation of receptor tyrosine kinases, thereby promoting signalling. Certain peptidases can signal directly to cells, by cleaving GPCR to initiate intracellular signalling cascades. Intracellular peptidases also regulate GPCRs; lysosomal peptidases destroy GPCRs in lysosomes to permanently terminate signalling and mediate down-regulation; endosomal peptidases cleave internalized peptide agonists to regulate GPCR recycling, resensitization and signalling; and soluble intracellular peptidases also participate in GPCR function by regulating the ubiquitination state of GPCRs, thereby altering GPCR signalling and fate. Although the use of peptidase inhibitors has already brought success in the treatment of diseases such as hypertension, the discovery of new regulatory mechanisms involving proteolysis that control GPCRs may provide additional targets to modulate dysregulated GPCR signalling in disease.
肽酶的酶活性必须受到严格调节,以防止肽键的不受控制水解,这可能对生物系统产生破坏性影响。肽酶通常以无活性的原肽酶形式产生,与内源性抑制剂一起分泌,或者它们被分隔开。原肽酶在被其他肽酶通过蛋白水解去除 N 端激活肽后变得活跃。一些肽酶仅在特定 pH 值下对底物变得活跃,从而将活性限制在特定的隔室或条件下。这篇综述讨论了蛋白水解在调节 GPCR 方面所起的不同作用。在细胞表面,某些 GPCR 受到膜锚定肽酶对生物活性肽的水解失活的调节,从而阻止信号转导。相反,细胞表面肽酶也可以生成生物活性肽,直接激活 GPCR。或者,被 GPCR 激活的细胞表面肽酶可以生成生物活性肽,从而激活受体酪氨酸激酶的转激活,从而促进信号转导。某些肽酶可以通过切割 GPCR 直接向细胞发出信号,启动细胞内信号级联反应。细胞内肽酶也调节 GPCR;溶酶体肽酶在溶酶体中破坏 GPCR,以永久终止信号转导并介导下调;内体肽酶切割内化的肽激动剂,以调节 GPCR 再循环、再敏化和信号转导;可溶性细胞内肽酶还通过调节 GPCR 的泛素化状态参与 GPCR 功能,从而改变 GPCR 信号转导和命运。尽管使用肽酶抑制剂已在治疗高血压等疾病方面取得了成功,但发现涉及控制 GPCR 的蛋白水解的新调节机制可能为调节疾病中失调的 GPCR 信号转导提供额外的靶标。